RT Journal Article
SR Electronic
T1 Prospective SARS-CoV-2 cohort study among general practitioners during the second COVID-19 wave in Flanders, Belgium
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.26.21254327
DO 10.1101/2021.03.26.21254327
A1 Joachim Mariën
A1 Ann Ceulemans
A1 Diana Bakokimi
A1 Christine Lammens
A1 Margareta Ieven
A1 Stefan Heytens
A1 An De Sutter
A1 Jan Y Verbakel
A1 Ann Van den Bruel
A1 Herman Goossens
A1 Pierre Van Damme
A1 Kevin K. Ariën
A1 Samuel Coenen
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.26.21254327.abstract
AB Primary health care providers (PHCPs), especially general practitioners (GPs) are essential to organise health care efficiently. During the COVID-19 pandemic, they also keep the pressure off hospitals. PHCPs are assumed to be at high risk of a COVID-19 infection, as they are exposed to a large portion of the population (usually with less personal protective equipment than other frontline health care workers(HCWs)). Nevertheless, previous seroprevalence studies focussed on the general population or HCWs in hospital settings, rather than PHCPs. The aim of this study was to determine the seroprevalence of PHCPs after the first and during the second SARS-CoV-2 wave in Flanders (Belgium) and compare it to the seroprevalence in the general population (blood donors). A prospective cohort of PHCPs, mainly GPs (n=698) was screened for IgG antibodies against SARS-CoV-2 at five different time-points (June-December 2020). The dried blood spots they produced were analysed using a Luminex multiplex immunoassay. The seroprevalence of PHCPs remained stable between June and September 2020 (4.6-5.0%), but increased significantly from October to December (8.1-13.4%) 2020. The seroprevalence of PHCPs was not significantly higher than the seroprevalence of the blood donors at the end of December 2020. In conclusion, the sharp increase in seroprevalence during the second COVID-19 wave in Flanders shows that PHCPs were more at risk during the second wave compared to the first one. However, the increase was in line with the general population suggesting that PHCPs mainly got infected in their private settings.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov Identifier: NCT04779424Clinical Protocols https://www.clinicaltrials.gov/ct2/show/NCT04779424 Funding StatementThe work was funded by the University of Antwerp (BOF/COVID 42828), the RECOVER project (European Unions Horizon 2020 research and innovation programme; No 101003589), the Research Foundation Flanders (FWO) (G0G4220N and G054820N), the Health Care Worker seroprevalence study (Sciensano/ITM), NCT04373889 and intramural funds from the Institute of Tropical Medicine Antwerp. Joachim Marien is currently a research assistant of Research Foundation Flanders (FWO).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was given by the institutional review board of the Antwerp University Hospital/University of Antwerp (20/24/315). The study was registered as a clinical trial (ClinicalTrials.gov Identifier: NCT04779424) All participants provided informed consent to participate. We declare that the planning conduct and reporting of the study was in line with the Declaration of Helsinki, as revised in 2013.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.